Inventor · disambiguated record
Lei Jiang
Also filed as: JIANG LEI
18 granted patents·16 pending applications·20 citations·filing 2007–2025
88Inventor score
Files withSHANGHAI ENNOVABIO PHARMACEUTICALS CO LTD7MODERNATX INC5NOVARTIS AG4ENNOVABIO ZHEJIANG PHARMACEUTICALS CO LTD3SHANGHAI HAIHE PHARMACEUTICAL CO LTD3
Top patents by PatentIndex Score
34 records- 0183US8410264B2Heterocyclic oxime compoundsDAI MIAO·Filed 2010·Granted Apr 2, 2013·9 cites·17 claims
- 0283US7943652B2Hydroxamate-based inhibitors of deacetylases BNOVARTIS AG·Filed 2009·Granted May 17, 2011·6 cites·42 claims
- 0381US11897960B2Anti-IL-4R antibody and use thereofBEIJING WISDOMAB BIOTECHNOLOGY CO LTD·Filed 2018·Granted Feb 13, 2024·3 cites·18 claims
- 0475US12377136B2Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyriaMODERNATX INC·Filed 2022·Granted Aug 5, 2025·0 cites·11 claims
- 0575US2024024506A1Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemiaMODERNATX INC·Filed 2023·Application pending·0 cites
- 0671US8507676B2Heterocyclic oxime compoundsDAI MIAO·Filed 2012·Granted Aug 13, 2013·2 cites·15 claims
- 0763US2024108566A1Composition containing recombinant collagen with repairing and soothing effects, eye cream containing the composition and preparation method thereorMAYINGLONG MASSIVE HEALTH CO LTD·Filed 2023·Application pending·0 cites
- 0859US2025122221A1Six-membered cyclothiazole compound and use thereofNANJING ZAIMING PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0958US2025326842A1Anti-pvrig antibodies and methods of useBEIGENE SWITZERLAND GMBH·Filed 2025·Application pending·0 cites
- 1058US2022265856A1Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemiaMODERNATX INC·Filed 2018·Application pending·0 cites
- 1154US2020085916A1Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyriaMODERNATX INC·Filed 2017·Application pending·0 cites
- 1252US2024316165A1Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemiaMODERNATX INC·Filed 2022·Application pending·0 cites
- 1349US9062045B2Triazolopyridine compoundsCHEN CHAO·Filed 2012·Granted Jun 23, 2015·0 cites·15 claims
- 1447US12258336B2Preparation of seimicarbazide-sensitive amine oxidase inhibitor and use thereofSHANGHAI ENNOVABIO PHARMACEUTICALS CO LTD·Filed 2019·Granted Mar 25, 2025·0 cites·10 claims
- 1546US8349883B2Hydroxamate-based inhibitors of deacetylases BNOVARTIS AG·Filed 2011·Granted Jan 8, 2013·0 cites·34 claims
- 1643US2010022514A1Heterocycle Compounds and Methods of Use ThereofNORVARTIS AG·Filed 2007·Application pending·0 cites
- 1742US12486244B2Preparation of semicarbazide-sensitive amine oxidase inhibitor and use thereofENNOVABIO ZHEJIANG PHARMACEUTICALS CO LTD·Filed 2021·Granted Dec 2, 2025·0 cites·4 claims
- 1842US9474762B2Triazolopyridine compoundsCHEN CHAO·Filed 2015·Granted Oct 25, 2016·0 cites·1 claims
- 1942US2023271982A1Codrug that disintegrates in intestine, preparation therefor, and use thereofENNOVABIO ZHEJIANG PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 2041US12234232B2Aromatic heterocyclic compound with kinase inhibitory activitySHANGHAI ENNOVABIO PHARMACEUTICALS CO LTD·Filed 2019·Granted Feb 25, 2025·0 cites·9 claims
- 2140US12391687B2Five-and-six-membered heterocyclic compound and use thereof as protein receptor kinase inhibitorSHANGHAI ENNOVABIO PHARMACEUTICALS CO LTD·Filed 2019·Granted Aug 19, 2025·0 cites·8 claims
- 2240US2023293503A1Use of berberine analog and jak inhibitor in treatment of inflammatory diseases of gastrointestinal tractENNOVABIO ZHEJIANG PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 2340US2022017512A1Six-membered and six-membered heterocyclic compound and uses thereof serving as protein receptor kinase inhibitorSHANGHAI ENNOVABIO PHARMACEUTICALS CO LTD·Filed 2019·Application pending·0 cites
- 2440US2021347785A1Preparation and application of aromatic compound having immunoregulatory functionSHANGHAI ENNOVABIO PHARMACEUTICALS CO LTD·Filed 2019·Application pending·0 cites
- 2540US2022056023A1Preparation and application of class of n-containing heterocyclic compounds having immunoregulatory functionSHANGHAI ENNOVABIO PHARMACEUTICALS CO LTD·Filed 2019·Application pending·0 cites
- 2639US11191798B2Extracts of Andrographis paniculata, methods for preparation and use thereofNUTRITION SCIENCE PARTNERS LTD·Filed 2017·Granted Dec 7, 2021·0 cites·15 claims
- 2736US2011053925A1Hydroxamate-Based Inhibitors of DeacetylasesNOVARTIS AG·Filed 2010·Application pending·0 cites
- 2835US11787766B2Compound having PD-L1 inhibitory activity, preparation method therefor and use thereofSHANGHAI ENNOVABIO PHARMACEUTICALS CO LTD·Filed 2018·Granted Oct 17, 2023·0 cites·3 claims
- 2935US10682352B2Compound having mutant IDH inhibitory activity, preparation method and use thereofSHANGHAI HAIHE PHARMACEUTICAL CO LTD·Filed 2017·Granted Jun 16, 2020·0 cites·15 claims
- 3035US10562900B2Indazole compounds as FGFR kinase inhibitor, preparation and use thereofSHANGHAI HAIHE PHARMACEUTICAL CO LTD·Filed 2015·Granted Feb 18, 2020·0 cites·15 claims
- 3135US2011060009A1Hydroxamate-Based Inhibitors of DeacetylasesNOVARTIS AG·Filed 2010·Application pending·0 cites
- 3235US2013231373A1Hydroxamate-based inhibitors of deacetylasesBROOKS CLINTON ALAN·Filed 2010·Application pending·0 cites
- 3331US10968215B2Pyrido five-element aromatic ring compound, preparation method therefor and use thereofSHANGHAI HAIHE PHARMACEUTICAL CO LTD·Filed 2017·Granted Apr 6, 2021·0 cites·9 claims
- 3428US9896474B2(3A,9B,10A,13A,14B,17A,20S,22E)-ergosta-5,7,22-trien-3-ol and methods of preparing and using the sameZHENGYUANTANG TIANJIN BINHAI NEW AREA BIOTECH CO LTD·Filed 2016·Granted Feb 20, 2018·0 cites·3 claims
Join the waitlist — get patent alerts
Get an alert when Lei Jiang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →